INTANGIBLE ASSETS

The following table summarizes our intangible assets, net (in millions):



	September 30, 2018										December 31, 2017
	Gross Carrying Amount		Accumulated Amortization			Foreign Currency Translation Adjustment			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Finite-lived intangible assets:
Intangible asset - sofosbuvir	$	10,720	$	(3,379	)	$	—		$	7,341	$	10,720	$	(2,855	)	$	7,865
Intangible asset - axicabtagene ciloleucel (DLBCL)	6,200		(330		)	—			5,870		6,200		(72		)	6,128
Intangible asset - Ranexa	688		(650		)	—			38		688		(566		)	122
Other	546		(347		)	(1		)	198		546		(311		)	235
Total finite-lived intangible assets	18,154		(4,706		)	(1		)	13,447		18,154		(3,804		)	14,350
Indefinite-lived intangible assets - IPR&D	2,867		—			—			2,867		2,750		—			2,750
Total intangible assets	$	21,021	$	(4,706	)	$	(1	)	$	16,314	$	20,904	$	(3,804	)	$	17,100

Amortization expense related to finite-lived intangible assets is included in Cost of goods sold on our Condensed Consolidated Statements of Income and totaled $301 million and $902 million for the three and nine months ended September 30, 2018, respectively, and $209 million and $629 million for the three and nine months ended September 30, 2017, respectively.

As of September 30, 2018, the estimated future amortization expense associated with our finite-lived intangible assets is as follows (in millions):



Fiscal Year	Amount
2018 (remaining three months)	$	301
2019	1,088
2020	1,064
2021	1,064
2022	1,064
Thereafter	8,866
Total	$	13,447